Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sarepta’s ESSENCE Trial Gets FDA Panel Nod For Protocol Changes

Executive Summary

US agency’s experts unanimously support allowing use of in-dwelling ports to aid infusions in trial of two Duchenne muscular dystrophy compounds, while also endorsing the two-year, double-blind, placebo-controlled design, which was influenced by the clinical experience with Exondys 51 (eteplirsen).

Advertisement

Related Content

Sarepta Protocol Changes Could Impact Future Duchenne Trials
Recent And Upcoming FDA Advisory Committee Meetings
Sarepta Trial Protocol Changes May Ignite Debate On Placebo Design
Eteplirsen Revisited? FDA Panel To Weigh Protocol Changes For Two Sarepta Drugs
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120684

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel